Literature DB >> 8563761

Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis.

M A Blasco1, M Rizen, C W Greider, D Hanahan.   

Abstract

Telomeres consist of short repeated sequences that are synthesized by telomerase, a ribonucleo-protein DNA polymerase. Telomerase activity is present in many tumours and not detected in many normal tissues. Telomere shortening in human and mouse tissues and primary cell cultures may be due to the absence of telomerase activity. To determine when telomerase is activated during tumour development and progression, we examined telomerase activity and expression of the recently cloned mouse telomerase RNA component (mTR) in two different transgenic mouse models of multi-stage tumorigenesis. These mouse models allow examination of many independent tumours from genetically identical individuals. These mice reproducibly develop pancreatic islet cell carcinoma and squamous cell carcinoma of the skin. In both carcinoma types, we detected telomerase activity only in late-stage tumours; in contrast, we found mTR levels were upregulated in the early preneoplastic stages, and further increased during progression. Surprisingly, mTR levels did not parallel the amount of telomerase activity detected and a subset of tumours lacked telomerase activity and yet expressed telomerase RNA. Regulation of telomerase activity may therefore be separable from expression of its RNA component. These results clearly demonstrate telomerase is activated in late stages of tumour progression, and show for the first time that the initial up regulation of telomerase RNA is an early event, concurrent with the hyperproliferation elicited by viral oncogenes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8563761     DOI: 10.1038/ng0296-200

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  72 in total

Review 1.  Crisis intervention: the role of telomerase.

Authors:  A J Lustig
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  Telomere length regulation during postnatal development and ageing in Mus spretus.

Authors:  G M Coviello-McLaughlin; K R Prowse
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

3.  E2F-1 represses transcription of the human telomerase reverse transcriptase gene.

Authors:  D L Crowe; D C Nguyen; K J Tsang; S Kyo
Journal:  Nucleic Acids Res       Date:  2001-07-01       Impact factor: 16.971

4.  Telomerase extracurricular activities.

Authors:  Sandy Chang; Ronald A DePinho
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

5.  The catalytic subunit of yeast telomerase.

Authors:  C M Counter; M Meyerson; E N Eaton; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

6.  Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies.

Authors:  M A Trudeau; J M Y Wong
Journal:  Curr Pharmacogenomics Person Med       Date:  2010-03-01

Review 7.  Telomerase activity, cell proliferation, and cancer.

Authors:  C W Greider
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

8.  Expression of mouse telomerase catalytic subunit in embryos and adult tissues.

Authors:  L Martín-Rivera; E Herrera; J P Albar; M A Blasco
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

9.  Cooperation between p53 mutation and high telomerase transgenic expression in spontaneous cancer development.

Authors:  Eva González-Suárez; Juana M Flores; María A Blasco
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

10.  Herpesvirus telomerase RNA(vTR)-dependent lymphoma formation does not require interaction of vTR with telomerase reverse transcriptase (TERT).

Authors:  Benedikt B Kaufer; Sascha Trapp; Keith W Jarosinski; Nikolaus Osterrieder
Journal:  PLoS Pathog       Date:  2010-08-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.